Endometrial Cancer Market 2019 | Top Industry Players: ARIAD PHARMACEUTICALS, ABBOTT LABORATORIES, BECTON DICKINSON & CO., GLAXOSMITHKLINE, MERCK, NOVARTIS AG, SANOFI, SIEMENS HEALTHCARE

The Endometrial Cancer Market is expected to witness a lucrative growth during the forecast period. Endometrial cancer is the malignancy that develops in the layers of the cells that forms the endometrium, lining of uterus. Women with high blood pressure, diabetes, or breast cancer are at a greater risk of being affected with endometrial cancer. According to the American Cancer Society, in 2017, about 61,380 new cases of uterus body cancer have been diagnosed, and about 10,920 women died due to the uterine cancer. This market is likely to witness a significant growth, leading to an increase in the opportunity for the drug manufacturers.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16772
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Rising of the Healthcare Expenditure
The rising healthcare expenditure among the urban population and the initiatives taken by various governments for improving their healthcare infrastructure, is fueling the global endometrial cancer market. The presence of the equitable, responsive, and efficient health systems present across the countries in North America, Europe, and the Asia-Pacific has contributed to the maximum share of the GDP being utilized as healthcare expenditure. The US healthcare expenditure has grown by 5.8% in 2015, amounting to USD 3.03 trillion or USD 9,451 per person. Norway and Switzerland are the next big spenders on health per capita. Some of the other countries with maximum healthcare spending includes Germany, Canada, and the Netherlands, among others. The above given statistics shows that the overall expenditure for healthcare is on a rise in many of the countries, thus driving the market for endometrial cancer.
The other factors driving the market for the endometrial cancer include rise in awareness of uterine diseases and their available therapies, innovation in drug development, and growth of diagnostic tests.

Key Developments in the Market
January 2018: Eisai and Merck receive a breakthrough therapy designation from FDA for LENVIMA (lenvatinib mesylate) and KEYTRUDA (pembrolizumab) as a combination therapy for the advanced and/or metastatic renal cell carcinoma.

Major Players:
ARIAD PHARMACEUTICALS, ABBOTT LABORATORIES, BECTON DICKINSON & CO., GLAXOSMITHKLINE, MERCK, NOVARTIS AG, SANOFI, SIEMENS HEALTHCARE, AND ROCHE, amongst others.

Request Discount on this report @ https://marketprognosis.com/discount-request/16772
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Adverse Side-effects of Treatment
There are various side effects of cancer therapy, and the endometrial cancer, on its own, can produce symptoms such as the vaginal bleeding, pain during intercourse, and persistent pain in the lower abdomen or the pelvic area. Also, there are side-effects caused by these therapies which includes fever, fullness due to fluid in the abdomen, anemia, swelling caused by lymphedema, blood clots, difficulty urinating or constipation, and shortening of the vagina. The radiation therapy also has several side-effects, such as fatigue, dryness, itching, tightening, and burning in the vagina. These short-term side-effects are restraining the endometrial cancer market.
The other factors restricting the endometrial cancer market are low success rate in clinical trials for cancer drugs and high-costs associated with the treatment.

North America Dominates the Market
North America holds the major market, owing to the large number of research and development activities, along with high healthcare expenditure. In the United States, endometrial cancer is the most common type cancer of the female reproductive system and is the fourth most common cancer among women. Europe is expected to hold the second largest share in the global market, due to the growing product availability in the regions.

Enquiry Before Buying@ https://marketprognosis.com/enquiry/16772
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.